Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
There is currently no verifiable scientific information regarding a molecule or gene named "RNF186 antisense RNA 1" or "RNF186-AS1." Unlike characterized lncRNAs such as RNF185-AS1[3], RNF186-AS1 is not referenced in key biomedical repositories or peer-reviewed publications. The nomenclature suggests it may be a hypothetical or misattributed antisense transcript of the *RNF186* gene, which itself encodes a well-established E3 ubiquitin ligase involved in intestinal immune homeostasis and inflammatory disease[1][2][4]. However, the antisense RNA of *RNF186* has not been characterized, implicated in disease, or targeted by therapeutic drugs. There is a risk of confusion with other bona fide antisense RNAs (e.g., RNF185-AS1), and queries about "RNF186-AS1" likely reflect either a search error, a speculative entry, or missing data. **Note:** If you are searching for the antisense RNA of RNF185 (*RNF185-AS1*), that is a distinct, functionally characterized lncRNA implicated in thyroid cancer and cell proliferation[3]. For *RNF186* itself (not the antisense RNA), see sources for its function in innate immunity and inflammation[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF186 antisense RNA 1 (RNF186-AS1).